SLC5A2 and chronic kidney disease: Some anti-diabetic drugs, such as SGLT2 inhibitors (SGLT2i) and GLP-1 receptors agonists (GLP-1 RA), have been shown to contribute to weight loss and to prevent and treat T2DM, CKD, and HF, as well as decrease the risk of other CVD outcomes [9,10,11,12].